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0019-4832/Copyright © 2015, Cardiological SoTo diagnose and manage hypertension, recently various
regional and global guidelines have been published. Whereasresult is confusion, not clarity.Cardiovascular Disease (CVD) is the foremost cause of illness,
disability, and death in India according to the World Health
Organization (WHO). CVD contributes to >50% mortality in
India and growing!! Unfortunately, a large number of people
experiencing CVD are under the age of 60 years which affects
the overall public health status in India. The factors contrib-
uting to CVD burden in India include-hypertension, diabetes,
obesity, sedentary life, and tobacco consumption.1,2
Chronic hypertension is a powerful risk factor for CVD in
India. Epidemiological studies conducted in India in the last
six decades suggest an escalating prevalence of hypertension
both in the urban and rural areas and in both the genders.3e5
Some observational studies indicate that the incidence of
hypertension is anywhere between 30% and 40% of the adult
population.6 The totality of evidence reflects the overall inci-
dence of hypertension to be close to 30%. The prevalence is
higher in selected subgroups such as the elderly and those
who have diabetes/metabolic syndrome. Suffice it to say that
irrespective of the changing guidelines and definitions, hy-
pertension in India is a major public health problem. Unless
we give hypertension a top priority, Indian population is at a
high risk for CVD and its consequences.gement, Apollo Blood Pre
.com.
ciety of India. All rightsthe intent of so-called “Hypertension Guidelines” is to guide
themedical community to treat hypertension effectively, they
have caused needless confusion, disagreement, and discon-
tent. The very intent of the guidelines loses its value when the
The medical communities around the world which have
yearned for about a decade for updated “guidance” on the
management of hypertension got what they did not wishd-
plentiful confusing guidelines. Hypertension guidelines (and
advisories) poured in from the Hypertension Society of India.
European Society of Cardiology/European Society of Hyper-
tension/American Heart Association/American College of
Cardiology/report from the pastmembers of the Joint National
Committee 8/minority report from somemembers of past JNC
8/and the American Society of Hypertension/International
Society of Hypertension7e12 (Table 1). The diverse and incon-
sistent guidelines from respected professional bodies and in-
dividuals have caused in my opinion, needless agitation
bordering on disorder. While various guidelines have a com-
monmission of reducing the global burden of CVD, they differ
modestly on the cut-off points for target blood pressure levels
and in special populations. The conflicting recommendations
from various but well meaning sources created chaos and
doubts in the minds of health care professionals and public
health experts. While the differences may be small, the
pandemonium level was high enough in questioning whether
we need any more hypertension guidelines?
Systemic hypertension remains an important cause of
premature morbidity and excessive global mortality.13e16 In
most countries, hypertension has become the chief cause ofssure Clinics, Apollo Hospitals, Hyderabad, India.
reserved.
Table 1 e Classification of blood pressure (Age 18 &
above) Indian guidelines 2013.7
Category SBP (mmHg) DBP (mmHg)
Optimal <120 <80
Normal <130 <85
High normal 130e139 85e89
Hypertension
Stage 1 140e159 90e99
Stage 2 160e179 100e109
Stage 3 >180 >110
ISH
Grade I 140e159 <90
Grade II >160 <90
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that hypertension should be diagnosed and aggressively
treated, blood pressure control rates around the world are
abysmally low and shameful. Since hypertension truly is a
“silent” killer and remains undetected, CVD progression de-
fies boundaries. Rampant CVD exerts enormous health and
economic burdens on the affected individual, the family, the
society, and nation as a whole. In other words, the adverse
impact of hypertension extends beyond the individual and
should be viewed as a contagion. With ample evidence that
high levels of blood pressure are detrimental and that hy-
pertension can be effectively treated, it is inappropriate to
give mixed signals to the medical community and health
policy makers. From diverse sources of information that pa-
tients get in this digital age, it is extremely risky to imply that
blood pressure level targets should be loosened. I have
argued in various forums that the main problem in patients
with hypertension is “high” blood pressure not “low” blood
pressure. We should be more worried about hypertension,
not hypotension. Surely, one would avoid excessive or un-
wanted degree of blood pressure lowering in patients with
hypertension; it only needs common sense not guideline
committees.
The recommendations made by the individual members
of JNC 810 are very narrow in scope and of possible interest to
“academicians” who seek evidence-based strategies but not
of much practical value to the health care providers who
actually treat hypertension. One exampledthe guidelines
from the past members of JNC 8 suggest a threshold of >150/
90 mm Hg for patients 60 years or older whereas the ASH/ISH
guidelines12 apply that level of BP threshold for patients >80
years. The suggestion for age dependent criteria for hyper-
tension management made by the erstwhile JNC 8 were made
on the basis of hand-picked studies in the elderly. The
recommendation was based on the observation that a sys-
tolic BP of <140 mm Hg was not superior to <150 mm Hg.
However, in the studies they cited, no harm was induced at a
systolic BP <140 mm Hg. In contrast, the ASH/ISH guidelines
suggest a threshold of <140/90 mm Hg for patients between
ages 60 and 80 on the basis of data from 3 large stud-
iesdALLHAT, VALUE, and ACCOMPLISH.12 The threshold for
<150 mm Hg (as opposed to <140 mm Hg) applies only if you
are 80 years of age or older. This has been a contentious
point. Who can really argue that for a 60 year old, a systolic
BP level <140 mm Hg is embarrassing!!. The proposal madeby the JNC 8 panel members that the target BP for patients
over 60 should be >150/90 mm Hg has the potential of
misinterpretation and laxity at a time when there is a hue
and cry to improve the hypertension control rates in all ages.
The elderly group is of paramount importance because of
high risk, disease vulnerability, and high rates of “resistant”
hypertension.17 The burden of proof provided by the JNC 8
members was insufficient to reduce the burden of CVD.
The BP targets recommended by 2013 European guidelines
are less aggressive than before but for most patients the goal
should be <140/90 mm Hg which makes sense. For hyperten-
sive patients with diabetes, the diastolic BP target is
<85mmHgwhich alsomakes sense.18 Let us not grumble over
80 mm Hg or 85 mm Hg.
The minority view from some members of the JNC 8
panel11 offers substantial evidence that a systolic BP
<140 mm Hg in patients over 60 years confers enormous
health benefits particularly in the absence of diabetes or
chronic kidney disease (CKD). A target BP level of <140 mmHg
for individuals less than 80 years of age in recommended by
atleast five national and international professional
organizations.8,9,12,19,20
The lack of benefit from aggressive treatment of hyper-
tension in the elderly was seen in two studiesdJapanese Trial
to Assess Optimal Systolic Blood Pressure in Elderly (JATOS)21
and Valsartan in Elderly Isolated Systolic Hypertension (VAL-
ISH).22 But these studies vastly underpowered, had low com-
posite event rates (125 strokes and 67 coronary events). In
contrast, an elderly hypertension study (FEVEReFelodipine
Event Reduction)23 which was considered by the ESC/ESH
panel but not by the JNC 8 members reported safety and sig-
nificant therapeutic benefits in patients treated to a systolic
BP-137 mm Hg (Table 2). Effective treatment of hypertension
in the elderly is not rocket science but the benefits are spec-
tacular in limiting the occurrence of stroke and heart failure.
In sum, the scope of recommendations made by the JNC 8
panel members is limited by the narrow principle of evidence
based and selective criteria. The panel acknowledged that its
report is not comprehensive and does not cover many aspects
of hypertension evaluation and treatment such as ambulatory
blood pressure monitoring, variability of blood pressure;
work-up, and non-pharmacological therapy. Many patients
over the age of 60 years have obesity, and hyperlipidemia
which increases the CVD risk from hypertension. Hence, it is a
good thing to aim for optimal BP goals in this population.
The ASH/ISH guidelines (Fig. 1) suggest different (and
broader) drug choices for initial therapy compared to the
recommendations of JNC 8 panel members. While the
pointers from JNC 8 panel members on drug selection appear
restrictive, the ASH/ISH therapeutic suggestions truly provide
guidance on managing hypertension in the “community”.
While the JNC 8 panelists views on b-blockers are acceptable,
their recommendations on “thiazides” as a homogenous class
are unwarranted. There should have been a mention about
other diuretics. Moreover, other than in the elderly, the initial
choice of thiazides in younger patients is not based on evi-
dence. And chronic exposure to thiazides increases the risk of
new onset diabetes. There should have been an objective
statement on the place of aldosterone antagonists in the
treatment of resistant hypertension. The so-framed “evidence
Table 2 e Recent clinical trials in the elderly-systolic blood pressure as target.
Trial name Number of subjects Duration (years) End points Primary outcomes
HYVET24 3845 2.1 Any CVD: 331
Strokes:120
Deaths:431
HR: 0.61
p ¼ 0.046
JATOS21 4418 2 CVD or renal
Event: 172
Deaths: 17
Rate per 1000
Patient years: 22.6 vs. 22.7
p ¼ 0.99
VALISH22 3260 2.85 CVD or renal
Event: 99
Deaths: 54
HR: 0.89
(CI, 0.60e1.31)
p ¼ 0.383
FEVER23 9711 3.3 Any CVD: 575
Strokes: 428
Deaths: 263
HR: 0.73
p ¼ 0.0019
Fig. 1 e Algorithm offered in the ASH/ISH guidelines (from reference12).
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one titrates the drug dosage to meet the intended therapeutic
target level. Therefore there is no sensation about dosing. We
are not talking about chemotherapy.
The ASH/ISH guidelines are comprehensive and include
steps for evaluation, diagnosis, and management of hyper-
tension in the community taking into consideration “totality”
of the evidence from numerous published clinical trials of the
last decade. The ASH/ISH guidelines provide a user friendly
approach which can be easily followed by the health care
professionals at the point-of-contact with hypertensive pa-
tients. These guidelines are practical enough to suggest that
practitioners may wish to achieve lower than recommended
blood pressure targets at their discretion if the therapy is well
tolerated. This is a courageous statementdwe are after all,
health care providers not journalists. The ASH/ISH statement
comments on situations which matter to the practitio-
nersdresistant hypertension, white coat hypertension, 24 h
ABPM, cerebrovascular disease, dementia, CKD, diabetes,
microalbuminuria, coronary artery disease, heart failure, and
sleep apnea, etc. The ASH/ISH guidelines do not recommend
special target, for black patients other than stating that they
have severe forms of hypertension requiring closer surveil-
lance to achieve target BP levels.
As expected, there is much overlap between various
guidelines except for the age thresholds (60 vs 80) and systolic
blood pressure targets (140 vs 150). The best way to move
forward (not lateral) is to apply differing guidelines in a
complimentary fashion to render of “individualized” treat-
ment. No single size fits all!. In conclusion, the guidelines/
statements offer knowledge base but should not be viewed as
a substitute for sound clinical reasoning in making diagnostic
and therapeutic decisions to benefit the patient as an indi-
vidual, not as a group. The time has come for everlasting
single “global” guidelines document leaving room for regional/
cultural differences and ground realities. One non-
controversial recommendation, however, is that hyperten-
sion should be treated aggressively to prevent unrelenting
excessive morbidity and mortality from cardiovascular
disease.
A recent observational study25 involving nearly 400,000
patients with hypertension has yielded strikingly useful and
practically applicable findings. In this large cohort of real
world patients, the best clinical outcomes were in the patients
who achieved a systolic blood pressure level between 130 and
139 mm Hg and a diastolic blood pressure level between 60
and 79 mmHg. The nadir BP associated with best clinical
outcome and survival were 137 mmHg for systolic and
71 mmHg for diastolic (Table 3).
Hypertension is a serious condition; individuals with
hypertension are at high risk for a variety of systemicTable 3
Take home message from the KAISER Study25
400,000 patients with hypertension and 4 year follow-up
 Best SBP levels for outcome 130e139 mmHg
 Best DBP levels for outcome 60e80 mmHg
 Worst Prognosis e SBP <110 OR > 170 mmHg
DBP <50 OR >90 mmHgcomplications leading to significant morbidity and excessive
mortality. The global medical community should view hy-
pertension as a merciless killer. At a time when we have an
urgent task to enhance patient adherence to non-
pharmacological and pharmacological therapies, introduc-
tion of controversial headline grabbing recommendations
does not help the cause. Unfortunately, some recently
released hypertension guidelines do not present recom-
mendations on the benefit: risk ratios of therapeutic inter-
vention or inaction. Guidelines generally address broad
populations but it is the practitioner who has to decide
about individual patients. Although the rigorous process of
writing guidelines is complex, and a painful undertaking,
unseemly and incorrect recommendations based on
fragmentary information can result in unintended
consequences.
With the growing global disease burden from uncontrolled
hypertension, our responsibility is to diagnose and treat hy-
pertension aggressively, we can no longer afford to “wait and
see”; insteadwith a “war footing” hypertension control should
be achieved. Unless the consequences of uncontrolled hy-
pertension are contained, we will be guilty of passing on the
pandemic of CVD to the next generation. Act, we must now.
Without being distracted by the nuisance of guidelines con-
troversy, let us get our sight back and concentrate on
achieving aggressive BP blood pressure control rates around
the world.
Take home practical points:
 The threshold to treat hypertension should be 140/
90 mm Hg in all patients <80 years.
 For individuals >80 years, the threshold to treat hyper-
tension should be 150/90 mm Hg.
 For patients with chronic kidney disease CVD, diabetes,
and proteinuria, the blood pressure target should be be-
tween 130/80 mm Hg and 140/90 mm Hg.
 Keep in mind what I stated elsewhere e the issue in pa-
tients with hypertension is “high” blood pressure and not
“low” blood pressure. No one is asking you to lower the BP
levels deliberately to 110/60 mm Hg or 90/50 mm Hg.
Common sense is still valid.
 Do not loosen the goal blood pressure levels but focus on
achieving a blood pressure of <140/90 mmHg in persons
under the age of 80 years; for individuals older than 80
years, achieve (if possible) the blood pressure level of 150/
90 mmHg.
 Simple, no confusion, straight forward, and go for it.Conflicts of interest
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